- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.34
5.86
52 wk Range
5.23
50.40
LENZ Earnings
View the latest LENZ Therapeutics earnings results, revenue figures, and LENZ Therapeutics earning report, including the LENZ Therapeutics earnings dates and reported performance.
Latest Release
May 11, 2026
EPS / Forecast
-1.32 / -1.17
Revenue / Forecast
1.9M / --
All numbers in USD
LENZ Therapeutics Inc Earnings Call Summary for Q1/2026
- LENZ reported Q1 2026 net revenue of $1.9M with prescriptions up 19% quarter-over-quarter, though posted a $41.5M net loss ($1.32/share).
- Company maintains strong liquidity with $258.4M in cash and equivalents despite elevated SG&A expenses of $45M, up 13% from prior quarter.
- Stock rose 3.28% after-hours but remains down 62% over six months, trading at $9.99 versus 52-week high of $50.40; market cap at $312.9M.
- Management projects continued growth through DTC campaigns and sales force expansion, with improved manufacturing processes expected to boost availability.
- Key risks include supply chain disruptions, competitive pressures in presbyopia market, and sustainability concerns amid high cash burn rate.
Last Updated: 2026-05-11, 05:48 p/m
Read Full TranscriptFAQ
What Is LENZ Therapeutics's Earnings Per Share (TTM)?
The LENZ Therapeutics EPS (TTM) is -3.66.
When Is The Next LENZ Therapeutics Earnings Date?
LENZ Therapeutics will release its next earnings report on Aug 19, 2026.
What Is LENZ Therapeutics’s Revenue Forecasts For Upcoming Quarters?
LENZ Therapeutics’s revenue forecast is 2.49M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.